A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

February 5, 2022

Study Completion Date

February 26, 2022

Conditions

Hepatic ImpairmentHealthy Volunteers

Interventions

DRUG

Mobocertinib

Mobocertinib capsule.

Trial Locations (2)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology of Miami, Hialeah